Screener
Eton Pharmaceuticals, Inc. ETON Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 67,095 | 65,960 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 50,000,000 shares authorized; 27,359,791 and 27,047,061 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 27 | 27 |
| Additional paid-in capital | 141,528 | 138,621 |
| Accumulated deficit | (110,940) | (112,494) |
| Total stockholders’ equity | 30,615 | 26,154 |
| Total liabilities and stockholders’ equity | $97,710 | $92,114 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s retained earnings?
- Eton Pharmaceuticals, Inc. (ETON) reported retained earnings of -$110.94M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Eton Pharmaceuticals, Inc.'s retained earnings decreased by 1.3% year-over-year, from -$109.47M to -$110.94M.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s retained earnings has grown at a 4.1% compound annual growth rate (CAGR), from -$92.16M to -$112.49M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Eton Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude